“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

- Dan Platt, M.D.
Chief Medical Officer

Our Deskside with Dr. Dan section highlights cancer news in a way you can understand! Dan Platt, M.D. pulls the most relevant information out of the medical news and puts it into the correct context so that you can understand its importance for your disease.

Our goal is to share relevant medical news, information about clinical trials, and key takeaways from recent FDA approvals so that you can feel informed and empowered to get the best treatment possible.

Deskside with Dr. Dan articles are not offering medical advice but are created to provide information to empower decisions. You should always consult your oncology team with any questions that you might have.

Filtering

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Myelodysplastic Syndromes
  • Non-Hodgkin Lymphoma
  • Skin Cancer

  • Clinical Trial
  • Coronavirus
  • FDA Approval

Multiple Myeloma Meetup: Program Recap (What It Is & Treatment Info)

Read a written recap of our Multiple Myeloma Meetup with MMRF, where the basics of what multiple myeloma is was discussed as well as treatment options and exciting developments in immunotherapy.


Multiple Myeloma Meetup with MMRF

In recognition of Multiple Myeloma Awareness Month, we are partnering with The Multiple Myeloma Research Foundation (MMRF) to bring you the latest information on treatments, research and resources for Multiple Myeloma.


FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma

Get Dr. Dan's medical perspective about the approval of carfilzomib and daratumumab with dexamethasone for multiple myeloma treatment.


FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma

Get Dr. Dan's medical perspective about the accelerated approval to belantamab mafodotin-blmf for multiple myeloma treatment.